60 results
8-K
EX-99.1
APLS
Apellis Pharmaceuticals Inc
27 Feb 24
Apellis Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results
7:30am
were partially offset by an increase in compensation and related personnel costs.
General and Administrative (G&A) Expenses.
G&A expenses were $141.7
8-K
EX-99.1
337p7
31 Jul 23
Apellis Pharmaceuticals Reports Second Quarter 2023 Financial Results
8:03am
424B5
5nov5c6blfhz1
24 Mar 22
Prospectus supplement for primary offering
8:02pm
424B5
n2kng1 8tls64fefln
23 Mar 22
Prospectus supplement for primary offering
5:14pm
424B5
0gipd8cit
17 Nov 21
Prospectus supplement for primary offering
9:02am
424B5
wkap 388x9vgk0la
15 Nov 21
Prospectus supplement for primary offering
5:24pm